{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:57:21Z","timestamp":1793761041293,"version":"4.6.1"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Ovarian cancer remains the most lethal gynecological malignancy worldwide, with late-stage diagnosis, high recurrence rates, and chemoresistance posing persistent clinical challenges. Adoptive cell therapy (ACT), a rapidly advancing immunotherapeutic strategy, offers promising efficacy with low systemic toxicity and has emerged as a compelling option to address these limitations. This review provides a comprehensive overview of ACT modalities\u2014including tumor-infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR-T), natural killer (NK) cells, and other emerging cellular therapies such as TCR-T, cytokine-induced killer (CIK) cells, and \u03b3\u03b4 T cells\u2014in the context of ovarian cancer. We highlight the mechanistic underpinnings of ACT, the immunosuppressive features of the ovarian tumor microenvironment, and cutting-edge advances in combinatorial regimens, genetic engineering, and cell design aimed at overcoming therapeutic resistance. In particular, we discuss antigen specificity, tumor immune evasion, and stromal barriers, and summarize current clinical trial progress, efficacy outcomes, and translational barriers. Together, these insights underscore the transformative potential of ACT in ovarian cancer and outline future directions for personalized and scalable immunotherapies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1794716","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T05:26:55Z","timestamp":1777267615000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in adoptive cell therapy for ovarian cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Na","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Affiliated Hospital of Binzhou Medical University","place":["Binzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"An","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Affiliated Hospital of Binzhou Medical University","place":["Binzhou, China"]},{"name":"Operating Room, Department of Anesthesiology, Affiliated Hospital of Binzhou Medical University","place":["Binzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanwei","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Affiliated Hospital of Binzhou Medical University","place":["Binzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Affiliated Hospital of Binzhou Medical University","place":["Binzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtang","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Affiliated Hospital of Binzhou Medical University","place":["Binzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhentao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Affiliated Hospital of Binzhou Medical University","place":["Binzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)01635-6","article-title":"The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"Force","year":"2025","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3390\/biomedicines13071525","article-title":"Management of advanced ovarian cancer: Current clinical practice and future perspectives","volume":"13","author":"Papageorgiou","year":"2025","journal-title":"Biomedicines"},{"key":"B3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12957-025-03770-w","article-title":"Comparative effectiveness and safety of treatment regimens for recurrent advanced ovarian cancer: A systematic review and network meta-analysis","volume":"23","author":"Huo","year":"2025","journal-title":"World J Surg Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40364-025-00818-7","article-title":"Therapeutic landscape of ovarian cancer: Recent advances and emerging therapies","volume":"13","author":"Wang","year":"2025","journal-title":"biomark Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3390\/cancers15020368","article-title":"Patient-derived in vitro models of ovarian cancer: Powerful tools to explore the biology of the disease and develop personalized treatments","volume":"15","author":"Battistini","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ijgo.70282","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2025 update","volume":"171","author":"Renz","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-024-07775-w","article-title":"Prognostic impact of microscopic residual disease after neoadjuvant chemotherapy in patients undergoing interval debulking surgery for advanced ovarian cancer","volume":"311","author":"Di Donato","year":"2025","journal-title":"Arch Gynecol Obstet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3390\/ijms27031207","article-title":"Special issue \u201cResistance to therapy in ovarian cancers","volume":"27","author":"Azzalini","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1595533","article-title":"Recent advances in tumor immunotherapy based on NK cells","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1153423","article-title":"Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1247178","article-title":"Editorial: Targeting metabolism to activate T cells and enhance the efficacy of checkpoint blockade immunotherapy in solid tumors","volume":"14","author":"Xia","year":"2023","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12051","article-title":"Cdc42 functions as a regulatory node for tumour-derived microvesicle biogenesis","volume":"10","author":"Wang","year":"2021","journal-title":"J Extracell Vesicles"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1697505","article-title":"The broad spectrum of cancer and immunotherapy: Achievements and limitations","volume":"16","author":"Aman","year":"2025","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1665488","article-title":"Recent advances in adoptive cell therapy for cancer immunotherapy","volume":"16","author":"Qian","year":"2025","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/medsci13030190","article-title":"Advances in adoptive cell therapies in cancer: From mechanistic breakthroughs to clinical frontiers and overcoming barriers","volume":"13","author":"Rabbani","year":"2025","journal-title":"Med Sci (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1677548","article-title":"Reprogramming the tumor microenvironment to boost adoptive T cell therapy","volume":"16","author":"Meza Pacheco","year":"2025","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3390\/biom15101407","article-title":"Advancing CAR-T therapy for solid tumors: From barriers to clinical progress","volume":"15","author":"Smirnov","year":"2025","journal-title":"Biomolecules"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"CAR-T cells in solid tumors: Challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12935-025-03938-0","article-title":"Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions","volume":"25","author":"Zhu","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013285","article-title":"Advancing adoptive T cell therapy in ovarian cancer: Barriers, innovations, and emerging platforms","volume":"14","author":"Santos","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.09.001","article-title":"Crosstalk of T cells within the ovarian cancer microenvironment","volume":"10","author":"Chap","year":"2024","journal-title":"Trends Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.3390\/cancers15194814","article-title":"The landscape of adoptive cellular therapies in ovarian cancer","volume":"15","author":"Davis","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-023-01378-3","article-title":"Non-invasive activation of intratumoural gene editing for improved adoptive T-cell therapy in solid tumours","volume":"18","author":"Chen","year":"2023","journal-title":"Nat Nanotechnol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00262-024-03884-2","article-title":"Cryo-thermal therapy reshaped the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy","volume":"74","author":"Wang","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B27","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s41573-023-00809-z","article-title":"T cell receptor therapeutics: Immunological targeting of the intracellular cancer proteome","volume":"22","author":"Klebanoff","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2563099","DOI":"10.1080\/2162402X.2025.2563099","article-title":"Natural killer cells in adoptive cell therapy: Current landscape of genetic engineering strategies","volume":"14","author":"Bur\u00f3n","year":"2025","journal-title":"Oncoimmunology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00262-025-04274-y","article-title":"Non-genetically modified adoptive cell therapies for solid tumors: Current landscape and future challenges","volume":"75","author":"Luo","year":"2026","journal-title":"Cancer Immunol Immunother"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.3390\/ijms24065688","article-title":"CAR T-cell persistence correlates with improved outcome in patients with B-cell lymphoma","volume":"24","author":"Wittibschlager","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2021.03.075","article-title":"Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis-new insight and futuristic vision","volume":"180","author":"Huang","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40364-025-00807-w","article-title":"T cells in cancer: Mechanistic insights and therapeutic advances","volume":"13","author":"Pu","year":"2025","journal-title":"biomark Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e012822","DOI":"10.1136\/jitc-2025-012822","article-title":"Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time","volume":"13","author":"Salas-Benito","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1658795","article-title":"Progress in targeting tumor-associated macrophages in cancer immunotherapy","volume":"16","author":"Xia","year":"2025","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1121030","article-title":"Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells","volume":"14","author":"Hiltensperger","year":"2023","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e013211","DOI":"10.1136\/jitc-2025-013211","article-title":"MMP3 overexpression enhances CAR-T cell infiltration and antitumor activity in a CAF-enriched solid tumor model","volume":"14","author":"Zhu","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00368-z","article-title":"Chimeric antigen receptor-T cells for targeting solid tumors: Current challenges and existing strategies","volume":"33","author":"Springuel","year":"2019","journal-title":"BioDrugs"},{"key":"B38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/cr.2016.154","article-title":"Driving gene-engineered T cell immunotherapy of cancer","volume":"27","author":"Johnson","year":"2017","journal-title":"Cell Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03529-w","article-title":"Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1","volume":"72","author":"Mun","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.3390\/cancers16132483","article-title":"Modulating tumor immunity by targeting tumor fibrotic stroma and angiogenic vessels for lung cancer treatment","volume":"16","author":"Yuan","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ygyno.2024.04.001","article-title":"Adoptive T cell therapy for ovarian cancer","volume":"186","author":"Gitto","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba7308","article-title":"A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci Transl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.837230","article-title":"Adenosine-A2A receptor pathway in cancer immunotherapy","volume":"13","author":"Sun","year":"2022","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-025-01112-2","article-title":"Tumor-infiltrating lymphocyte expansion protocols for adoptive cell therapy in cancer","volume":"48","author":"Tovar Manzano","year":"2025","journal-title":"Cell Oncol (Dordr)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000566","article-title":"Tumour-infiltrating lymphocyte therapy landscape: Prospects and challenges","volume":"4","author":"Chen","year":"2025","journal-title":"BMJ Oncol"},{"key":"B46","article-title":"Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer","volume":"51","author":"Aoki","year":"1991","journal-title":"Cancer Res"},{"key":"B47","article-title":"Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes","volume":"1","author":"Fujita","year":"1995","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-4322","article-title":"Effective TIL therapy for patients with checkpoint-resistant melanoma without lymphodepleting regimens requires IFN\u03b1","volume":"31","author":"Verdegaal","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0040-8","article-title":"Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer","volume":"24","author":"Zacharakis","year":"2018","journal-title":"Nat Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006822","article-title":"Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma","volume":"12","author":"Amaria","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.608485","article-title":"Global perspective on the development of genetically modified immune cells for cancer therapy","volume":"11","author":"Pinte","year":"2020","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"key":"B54","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/cancers16010040","article-title":"The role of cancer stem cell markers in ovarian cancer","volume":"16","author":"Fr\u0105szczak","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B55","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41698-025-00874-0","article-title":"ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial","volume":"9","author":"Herzog","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13073-024-01405-5","article-title":"Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study","volume":"16","author":"Xu","year":"2024","journal-title":"Genome Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1101\/2023.01.06.522784","article-title":"Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting","volume":"14","author":"Lee","year":"2023","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109173","article-title":"Basing on uPAR-binding fragment to design chimeric antigen receptors triggers antitumor efficacy against uPAR expressing ovarian cancer cells","volume":"117","author":"Wang","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10510","article-title":"Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1389971","article-title":"The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review","volume":"15","author":"Satapathy","year":"2024","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.114607","article-title":"Integrating CAR-T therapy with PD-1\/PD-L1 blockade: mechanisms, synergy, and optimized strategies in NSCLC","volume":"29","author":"Li","year":"2026","journal-title":"iScience"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001162","article-title":"\u03b1PD-1-mesoCAR-T cells partially inhibit the growth of advanced\/refractory ovarian cancer in a patient along with daily apatinib","volume":"9","author":"Fang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1113882","article-title":"The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies","volume":"14","author":"Daei Sorkhabi","year":"2023","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012599","article-title":"Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration","volume":"8","author":"Kostopoulos","year":"2024","journal-title":"Blood Adv"},{"key":"B65","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3390\/diagnostics14080819","article-title":"CAR-T cell therapy in ovarian cancer: where are we now","volume":"14","author":"Cutri-French","year":"2024","journal-title":"Diagn (Basel)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100804","article-title":"Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s44272-025-00044-0","article-title":"Management of cytokine release syndrome (CRS) following CAR T-cell therapy: a comprehensive review","volume":"4","author":"Zhang","year":"2025","journal-title":"JCCB"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2026.120115","article-title":"The role of cytokines in cytokine release syndrome (CRS) after CAR T cell therapy","volume":"1873","author":"Gabriel","year":"2026","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70069","article-title":"Cytokine release syndrome in solid tumors","volume":"131","author":"Synnott","year":"2025","journal-title":"Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"235","DOI":"10.35841\/aajcit-7.5.235","article-title":"Incidence and management of Cytokine release syndrome in CAR-T cell therapy for solid tumors: A systematic review of phase I trials","volume":"7","author":"Anand","year":"2024","journal-title":"JJCIT"},{"key":"B71","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40164-024-00542-2","article-title":"Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers","volume":"13","author":"Gu","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1622433","article-title":"CAR-T therapy-based innovations in the enhancement of contemporary anti-tumor therapies","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.02.028","article-title":"IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer","volume":"145","author":"Felices","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.11.006","article-title":"Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: results of the phase 1 INTRO-01 trial","volume":"204","author":"Hoogstad-van Evert","year":"2026","journal-title":"Gynecol Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-15-0118","article-title":"Phase I study of random healthy donor-derived allogeneic natural killer cell therapy in patients with Malignant lymphoma or advanced solid tumors","volume":"4","author":"Yang","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/ijms20030660","article-title":"Characterization of a novel third-generation anti-CD24-CAR against ovarian cancer","volume":"20","author":"Klapdor","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.88539","article-title":"NK-92MI cells engineered with anti-claudin-6 chimeric antigen receptors in immunotherapy for ovarian cancer","volume":"20","author":"Li","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: a phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.21417\/rh2023nm","article-title":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1\/2 trial interim results","volume":"29","author":"Hassan","year":"2023","journal-title":"Nat Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/435745","article-title":"Cytokine-induced NK-like T cells: from bench to bedside","volume":"2010","author":"Linn","year":"2010","journal-title":"J BioMed Biotechnol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00262-023-03605-1","article-title":"Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy","volume":"73","author":"Sharma","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1080","article-title":"\u03b3\u03b4 T cells in cancer: a small population of lymphocytes with big implications","volume":"8","author":"Raverdeau","year":"2019","journal-title":"Clin Transl Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40364-025-00762-6","article-title":"Gamma delta T cells and their immunotherapeutic potential in cancer","volume":"13","author":"Cieslak","year":"2025","journal-title":"biomark Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1177\/10732748251399242","article-title":"Mechanisms and applications of \u03b3\u03b4 T cells in anti-tumor immunity","volume":"32","author":"Zhang","year":"2025","journal-title":"Cancer Control"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1794716\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T05:26:56Z","timestamp":1777267616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1794716\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":85,"alternative-id":["10.3389\/fimmu.2026.1794716"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1794716","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"article-number":"1794716"}}